BRIGHT MINDS BIOSCIENCES INC.

New York City –  August 25, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming […] The post Bright Minds Biosciences to Present at Upcoming Conferences appeared first on Bright Minds.

New York and Vancouver, BC –  May 28, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and […] The post Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference appeared first on Bright Minds.

– Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD –   Vancouver, British Columbia, May 20, 2025 – Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for […] The post Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 appeared first on Bright Minds.

BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model – The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) – Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention –   New York and Vancouver, British Columbia, May 13, 2025 – Bright Minds Biosciences Inc. […] The post Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 appeared first on Bright Minds.

Vancouver, British Columbia, April 28, 2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May […] The post Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study appeared first on Bright Minds.

— Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O’Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug developmentand research to support Company’s clinical focus on epilepsy —   Vancouver, British Columbia, March 4,2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the […] The post Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research appeared first on Bright Minds.

New York and Vancouver, BC – February 24, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and […] The post Bright Minds Biosciences to Participate at Three Healthcare Conferences in March appeared first on Bright Minds.

— Dr. Collins brings extensive drug development and clinical expertise in epilepsy —   New York and Vancouver, BC – January 07, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other […] The post Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer appeared first on Bright Minds.

Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data –   NEW YORK, November 21, 2024 – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud […] The post Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting appeared first on Bright Minds.

Vancouver, British Columbia, November 4, 2024 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)announcesthat further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of1,612,902common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Sharefor aggregate gross proceeds […] The post BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT appeared first on Bright Minds.